Pfizer COVID-19 vaccine adult formulation COVID-19 vaccines Main navigation COVID-19 vaccines Moderna XBB.1.5 COVID-19 vaccine Pfizer XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Pregnant participants Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix® As part of the Australian COVID-19 vaccination program, AusVaxSafety is actively monitoring COVID-19 vaccines currently in use in Australia to ensure their ongoing safety. Vaccine safety surveillance through AusVaxSafety occurs in selected vaccination clinics around Australia, including state vaccination hubs, pharmacies, GPs and Aboriginal Community Controlled Health Organisations. Click on the tiles below to view AusVaxSafety COVID-19 vaccine safety data for individuals who received the adult 30 microgram formulation of the Pfizer COVID-19 vaccine. Pfizer COVID-19 vaccine safety data - All participants View the latest safety data here Pfizer COVID-19 vaccine safety data - Aboriginal and Torres Strait Islander participants View the latest safety data here Pfizer COVID-19 vaccine safety data - Adolescent participants View the latest vaccine safety data here Pfizer COVID-19 vaccine safety data - People affected by cancer and transplant recipients View the latest vaccine safety data here Pfizer COVID-19 vaccine safety data - pregnant participants View the latest safety data here COVID-19 vaccines Main navigation COVID-19 vaccines Moderna XBB.1.5 COVID-19 vaccine Pfizer XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Pregnant participants Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix® News & events All news & events 23 October 2024 | News AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses 01 October 2024 | News AusVaxSafety marks a decade of progress in vaccine safety 12 September 2024 | News AusVaxSafety surveillance of 2024 seasonal flu vaccines concludes with no safety issues identified 10 September 2024 | News Monitoring seasonal influenza vaccine safety in Australia: a proactive, collaborative approach